Richard A. Miller

Meet Richard A. Miller

In previous roles, Richard led the initial discovery and development efforts for ibrutinib (developed at Pharmacyclics) and research efforts on lymphoma, culminating in the development of rituximab (developed at IDEC; now Biogen). Today, he is also Adjunct Clinical Professor of Medicine (Oncology) at Stanford University Medical Center.